Is ALLO or ELVN more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Enliven Therapeutics N/A -21.04% -20.41%

Is ALLO or IDYA more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% IDEAYA Biosciences N/A -14.24% -13.09%

Is IRON or ALLO more profitable?

Disc Medicine's return on equity of -36.94% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -36.94% -33.88% Allogene Therapeutics N/A -56.45% -40.36%

Allogene Therapeutics (ALLO) Competitors

$2.13 +0.07 (+3.40%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$2.12 0.00 (-0.23%)

As of 06/26/2026 07:54 PM Eastern

Compare

ALLO vs. ELVN, IDYA, TARS, RARE, and IRON

Should you buy Allogene Therapeutics stock or one of its competitors? MarketBeat compares Allogene Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allogene Therapeutics include Enliven Therapeutics (ELVN), IDEAYA Biosciences (IDYA), Tarsus Pharmaceuticals (TARS), Ultragenyx Pharmaceutical (RARE), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry.

How does Allogene Therapeutics compare to Enliven Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Allogene Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Enliven Therapeutics' return on equity of -21.04% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Enliven Therapeutics has lower revenue, but higher earnings than Allogene Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	36,758.48	-$190.89M	-$0.77	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Allogene Therapeutics presently has a consensus price target of $8.52, suggesting a potential upside of 300.10%. Enliven Therapeutics has a consensus price target of $63.40, suggesting a potential upside of 26.60%. Given Allogene Therapeutics' higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Enliven Therapeutics had 8 more articles in the media than Allogene Therapeutics. MarketBeat recorded 9 mentions for Enliven Therapeutics and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.87 beat Enliven Therapeutics' score of 0.33 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allogene Therapeutics	Very Positive
Enliven Therapeutics	Neutral

Summary

Allogene Therapeutics beats Enliven Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Allogene Therapeutics compare to IDEAYA Biosciences?

Allogene Therapeutics (NASDAQ:ALLO) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

IDEAYA Biosciences has higher revenue and earnings than Allogene Therapeutics. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	36,758.48	-$190.89M	-$0.77	N/A
IDEAYA Biosciences	$218.71M	14.76	-$113.70M	-$1.60	N/A

Allogene Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market.

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, IDEAYA Biosciences had 3 more articles in the media than Allogene Therapeutics. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.87 beat IDEAYA Biosciences' score of 0.47 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allogene Therapeutics	Very Positive
IDEAYA Biosciences	Neutral

Allogene Therapeutics currently has a consensus target price of $8.52, indicating a potential upside of 300.10%. IDEAYA Biosciences has a consensus target price of $50.69, indicating a potential upside of 37.96%. Given Allogene Therapeutics' higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

IDEAYA Biosciences' return on equity of -14.24% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

Summary

Allogene Therapeutics and IDEAYA Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Allogene Therapeutics compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Tarsus Pharmaceuticals currently has a consensus price target of $90.67, suggesting a potential upside of 44.10%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 300.10%. Given Allogene Therapeutics' higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Tarsus Pharmaceuticals has higher revenue and earnings than Allogene Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.00	-$66.42M	-$1.14	N/A
Allogene Therapeutics	$20K	36,758.48	-$190.89M	-$0.77	N/A

In the previous week, Tarsus Pharmaceuticals had 8 more articles in the media than Allogene Therapeutics. MarketBeat recorded 9 mentions for Tarsus Pharmaceuticals and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.87 beat Tarsus Pharmaceuticals' score of 0.51 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tarsus Pharmaceuticals	Positive
Allogene Therapeutics	Very Positive

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Summary

Tarsus Pharmaceuticals beats Allogene Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Allogene Therapeutics compare to Ultragenyx Pharmaceutical?

Allogene Therapeutics (NASDAQ:ALLO) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Allogene Therapeutics currently has a consensus price target of $8.52, suggesting a potential upside of 300.10%. Ultragenyx Pharmaceutical has a consensus price target of $59.56, suggesting a potential upside of 93.57%. Given Allogene Therapeutics' higher probable upside, equities research analysts plainly believe Allogene Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Allogene Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 2 mentions for Ultragenyx Pharmaceutical and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.87 beat Ultragenyx Pharmaceutical's score of 1.69 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allogene Therapeutics	Very Positive
Ultragenyx Pharmaceutical	Very Positive

Allogene Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	36,758.48	-$190.89M	-$0.77	N/A
Ultragenyx Pharmaceutical	$673M	4.50	-$575M	-$6.11	N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Allogene Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Allogene Therapeutics' return on equity of -56.45% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Summary

Allogene Therapeutics beats Ultragenyx Pharmaceutical on 11 of the 16 factors compared between the two stocks.

How does Allogene Therapeutics compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Allogene Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Allogene Therapeutics	$20K	36,758.48	-$190.89M	-$0.77	N/A

In the previous week, Disc Medicine had 12 more articles in the media than Allogene Therapeutics. MarketBeat recorded 13 mentions for Disc Medicine and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.87 beat Disc Medicine's score of 0.18 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Disc Medicine	Neutral
Allogene Therapeutics	Very Positive

Disc Medicine's return on equity of -36.94% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Disc Medicine currently has a consensus price target of $105.80, suggesting a potential upside of 41.48%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 300.10%. Given Allogene Therapeutics' higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Allogene Therapeutics beats Disc Medicine on 8 of the 15 factors compared between the two stocks.

Get Allogene Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLO vs. The Competition

Export

Metric	Allogene Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$735.18M	$3.63B	$7.04B	$12.18B
Dividend Yield	N/A	2.23%	2.66%	6.24%
P/E Ratio	-2.77	21.56	26.13	24.17
Price / Sales	36,758.48	334.22	600.49	118.58
Price / Cash	N/A	141.14	47.95	55.62
Price / Book	1.64	8.33	10.78	6.36
Net Income	-$190.89M	$23.91M	$3.58B	$337.99M
7 Day Performance	6.50%	3.42%	2.22%	0.10%
1 Month Performance	-5.33%	0.39%	-0.09%	-1.28%
1 Year Performance	80.51%	65.22%	34.39%	27.68%

Allogene Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLO Allogene Therapeutics	3.2427 of 5 stars	$2.13 +3.4%	$8.52 +300.1%	+80.5%	$735.18M	$20K	N/A	310	Negative News High Trading Volume
ELVN Enliven Therapeutics	2.9938 of 5 stars	$45.96 +1.9%	$63.40 +37.9%	+142.2%	$2.75B	N/A	N/A	50
IDYA IDEAYA Biosciences	3.3593 of 5 stars	$34.23 +9.6%	$50.69 +48.1%	+71.9%	$2.74B	$218.71M	N/A	80
TARS Tarsus Pharmaceuticals	3.3223 of 5 stars	$63.56 +0.6%	$90.67 +42.6%	+55.9%	$2.72B	$451.36M	N/A	50	News Coverage Analyst Upgrade
RARE Ultragenyx Pharmaceutical	3.8664 of 5 stars	$29.03 +5.8%	$59.56 +105.2%	-15.7%	$2.70B	$670M	N/A	1,371	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLO) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allogene Therapeutics (ALLO) Competitors

ALLO vs. ELVN, IDYA, TARS, RARE, and IRON

How does Allogene Therapeutics compare to Enliven Therapeutics?

Summary

How does Allogene Therapeutics compare to IDEAYA Biosciences?

Summary

How does Allogene Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does Allogene Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does Allogene Therapeutics compare to Disc Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allogene Therapeutics (ALLO) Competitors

ALLO vs. ELVN, IDYA, TARS, RARE, and IRON

How does Allogene Therapeutics compare to Enliven Therapeutics?

Which has more volatility and risk, ALLO or ELVN?

Do insiders & institutionals have more ownership in ALLO or ELVN?

Is ALLO or ELVN more profitable?

Which has preferable earnings & valuation, ALLO or ELVN?

Do analysts recommend ALLO or ELVN?

Does the media refer more to ALLO or ELVN?

Summary

How does Allogene Therapeutics compare to IDEAYA Biosciences?

Which has stronger earnings and valuation, ALLO or IDYA?

Which has more risk & volatility, ALLO or IDYA?

Do insiders and institutionals have more ownership in ALLO or IDYA?

Does the media refer more to ALLO or IDYA?

Do analysts prefer ALLO or IDYA?

Is ALLO or IDYA more profitable?

Summary

How does Allogene Therapeutics compare to Tarsus Pharmaceuticals?

Do analysts rate TARS or ALLO?

Which has better earnings & valuation, TARS or ALLO?

Does the media prefer TARS or ALLO?

Do institutionals & insiders hold more shares of TARS or ALLO?

Which has more volatility & risk, TARS or ALLO?

Is TARS or ALLO more profitable?

Summary

How does Allogene Therapeutics compare to Ultragenyx Pharmaceutical?

Do analysts rate ALLO or RARE?

Which has more volatility & risk, ALLO or RARE?

Does the media prefer ALLO or RARE?

Which has better earnings & valuation, ALLO or RARE?

Do insiders & institutionals have more ownership in ALLO or RARE?

Is ALLO or RARE more profitable?

Summary

How does Allogene Therapeutics compare to Disc Medicine?

Which has better valuation and earnings, IRON or ALLO?

Does the media refer more to IRON or ALLO?

Is IRON or ALLO more profitable?

Which has more risk & volatility, IRON or ALLO?

Do analysts recommend IRON or ALLO?

Do institutionals & insiders hold more shares of IRON or ALLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools